Open AccessDual mTORC1/mTORC2 Inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis
Author(s) -
Rokeya Tasneen,
Deborah S. Mortensen,
Paul J. Converse,
Michael E. Urbanowski,
Anna M. Upton,
Nader Fotouhi,
Eric Nuermberger,
Natalie A. Hawryluk
Publication year - 2021
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00253-21
Subject(s) - pi3k/akt/mtor pathway , mtorc1 , mtorc2 , sirolimus , pharmacology , autophagy , mechanistic target of rapamycin , cancer research , biology , signal transduction , microbiology and biotechnology , apoptosis , biochemistry
Efforts to develop more effective and shorter-course therapies for tuberculosis have included a focus on host-directed therapy (HDT). The goal of HDT is to modulate the host response to infection, thereby improving immune defenses to reduce the duration of antibacterial therapy and/or the amount of lung damage.